HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE TABLETS.

ROSIGLITAZONE MALEATE and METFORMIN HYDROCHLORIDE tablets, for oral use
Initial U.S. Approval: 2002

WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS
See full prescribing information for complete boxed warning.

Rosiglitazone maleate: CONGESTIVE HEART FAILURE
- Thiazolidinediones, including rosiglitazone, cause or exacerbate heart failure in some patients (5.2). After initiation of rosiglitazone maleate and metformin hydrochloride tablets, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction must be considered. (5.3)

Metformin hydrochloride: LACTIC ACIDOSIS
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL. (5.1)
- Risk factors include renal impairment, concomitant use of certain drugs, age > 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information. (5.1)
- If lactic acidosis is suspected, discontinue rosiglitazone maleate and metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)

Recent Major Changes
- Boxed Warning 04/2017
- Dosage and Administration 04/2017
- Contraindications (4) 04/2017
- Warnings and Precautions (5.1) 04/2017

Indications and Usage
Rosiglitazone maleate and metformin hydrochloride tablets are a combination antidiabetic product containing a thiazolidinedione and a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1)

Important Limitations of Use:
- Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. (1)

Contraindications
- Hypersensitivity to rosiglitazone or any of the product’s ingredients. (4.1)

Warnings and Precautions
- Fluid retention, which may exacerbate or lead to heart failure, may occur. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk of other cardiovascular effects. (5.2)
- Meta-analysis of 52 mostly short-term trials suggested a potential risk of ischemic cardiovascular (CV) events relative to placebo, not confirmed in a long-term CV outcome trial versus metformin or sulfonylurea. (5.3)
- Dose-related edema (5.4), weight gain (5.5), and anemia (5.9) may occur.
- Measuring hematologic parameters annually. (5.9)

Adverse Reactions
- The most common adverse reactions (≥ 10%) include nausea/vomiting, diarrhea, headache, and dyspepsia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions
- inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels. (7.4)
- Inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. (7.1)
- Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use. (7.2)
- Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring. (7.3)
- Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake. (7.4)

Use in Specific Populations
- Pregnancy: No adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. (8.1)

Drug Interactions
- Nursing Mothers: Discontinue drug or nursing. (8.3)
- Safety and effectiveness in children younger than 18 years have not been established. (8.4)
- Geriatric Use: Assess renal function more frequently. (8.5)
- Hepatic Impairment: Avoid use in patients with hepatic impairment. (8.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

Revised: 04/2017
WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS

Rosiglitazone maleate: CONGESTIVE HEART FAILURE

- Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.2)]. After initiation of rosiglitazone maleate and metformin hydrochloride tablets, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of rosiglitazone maleate and metformin hydrochloride tablets must be considered.

- Rosiglitazone maleate and metformin hydrochloride tablets are not recommended in patients with symptomatic heart failure. Initiation of rosiglitazone maleate and metformin hydrochloride tablets in patients with established NYHA Class III or IV heart failure is contraindicated [see Contraindications (4), Warnings and Precautions (5.2)].

Metformin hydrochloride: LACTIC ACIDOSIS

- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL [see Warnings and Precautions (5.1)].

- Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.
• Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), Use in Specific Populations (8.6, 8.7)].

• If metformin-associated lactic acidosis is suspected, immediately discontinue rosiglitazone maleate and metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE
Rosiglitazone maleate and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Important Limitations of Use:

- Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, rosiglitazone maleate and metformin hydrochloride tablets should not be used in patients with type 1 diabetes.
- Coadministration of rosiglitazone maleate and metformin hydrochloride tablets with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)].

2 DOSAGE AND ADMINISTRATION
The dosage of antidiabetic therapy with rosiglitazone maleate and metformin hydrochloride tablets should be individualized on the basis of effectiveness and tolerability. The risk-benefit of initiating monotherapy versus dual therapy with rosiglitazone maleate and metformin hydrochloride tablets should be considered.

2.1 Starting Dose
Rosiglitazone maleate and metformin hydrochloride tablets are generally given in divided doses with meals.

All patients should start the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride tablets at the lowest recommended dose. Further increases in the dose of rosiglitazone should be accompanied by careful monitoring for adverse events related to fluid retention [see Boxed Warning, Warnings and Precautions (5.2)].

Patients Inadequately Controlled on Diet and Exercise: If therapy with a combination tablet containing rosiglitazone and metformin is considered appropriate for a patient with type 2 diabetes mellitus inadequately controlled on diet and exercise alone, the recommended starting dose of rosiglitazone maleate and metformin hydrochloride tablets is 2 mg/500 mg administered once or twice daily. For patients with HbA1c > 11% or fasting plasma glucose (FPG) > 270 mg/dL, a starting dose of 2 mg/500 mg twice daily may be considered. The dose of rosiglitazone maleate and metformin hydrochloride tablets may be increased in increments of 2 mg/500 mg per day given in divided doses if patients are not adequately controlled after 4 weeks. The maximum dose of rosiglitazone maleate and metformin hydrochloride tablets is 8 mg/2,000 mg per day.

Patients Inadequately Controlled on Rosiglitazone or Metformin Monotherapy: If therapy with a combination tablet containing rosiglitazone and metformin is considered appropriate for a patient with type 2 diabetes mellitus inadequately controlled on rosiglitazone or metformin monotherapy, then the selection of the dose of rosiglitazone maleate and metformin hydrochloride tablets should be based on the patient’s current doses of rosiglitazone and/or metformin.

To switch to rosiglitazone maleate and metformin hydrochloride tablets for patients currently treated with metformin, the usual starting dose of rosiglitazone maleate and metformin hydrochloride tablets is 4 mg rosiglitazone (total daily dose) plus the dose of metformin already being taken (see Table 1).
To switch to rosiglitazone maleate and metformin hydrochloride tablets for patients currently treated with rosiglitazone, the usual starting dose of rosiglitazone maleate and metformin hydrochloride tablets is 1,000 mg metformin (total daily dose) plus the dose of rosiglitazone already being taken (see Table 1).

When switching from combination therapy of rosiglitazone plus metformin as separate tablets, the usual starting dose of rosiglitazone maleate and metformin hydrochloride is the dose of rosiglitazone and metformin already being taken.

Table 1. Rosiglitazone Maleate and Metformin Hydrochloride Tablet Starting Dose for Patients Treated With Metformin and/or Rosiglitazone

<table>
<thead>
<tr>
<th>Prior Therapy</th>
<th>Usual Starting Dose of Rosiglitazone Maleate and Metformin Hydrochloride</th>
<th>Number of Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,000 mg/day</td>
<td>2 mg/500 mg</td>
<td>1 tablet twice a day</td>
</tr>
<tr>
<td>2,000 mg/day</td>
<td>2 mg/1,000 mg</td>
<td>1 tablet twice a day</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 mg/day</td>
<td>2 mg/500 mg</td>
<td>1 tablet twice a day</td>
</tr>
<tr>
<td>8 mg/day</td>
<td>4 mg/500 mg</td>
<td>1 tablet twice a day</td>
</tr>
</tbody>
</table>

1. For patients on doses of metformin between 1,000 and 2,000 mg/day, initiation of rosiglitazone maleate and metformin hydrochloride tablets requires individualization of therapy.

2.2 Dose Titration

Rosiglitazone maleate and metformin hydrochloride tablets are generally given in divided doses with meals, with gradual dose escalation. This reduces gastrointestinal side effects (largely due to metformin) and permits determination of the minimum effective dose for the individual patient.

Sufficient time should be given to assess adequacy of therapeutic response. FPG should be used initially to determine the therapeutic response to rosiglitazone maleate and metformin hydrochloride tablets. If additional glycemic control is needed, the daily dose of rosiglitazone maleate and metformin hydrochloride tablets may be increased by increments of 4 mg rosiglitazone and/or 500 mg metformin.

After an increase in metformin dosage, dose titration is recommended if patients are not adequately controlled after 1 to 2 weeks. After an increase in rosiglitazone dosage, dose titration is recommended if patients are not adequately controlled after 8 to 12 weeks.

2.3 Maximum Dose

The maximum recommended total daily dose of rosiglitazone maleate and metformin hydrochloride tablets is 8 mg rosiglitazone (taken as 4 mg twice daily) and 2,000 mg metformin (taken as 1,000 mg twice daily).

2.4 Specific Patient Populations

Renal Impairment: Assess renal function prior to initiation of rosiglitazone maleate and metformin hydrochloride tablets and periodically thereafter.

Rosiglitazone maleate and metformin hydrochloride tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m².

Initiation of rosiglitazone maleate and metformin hydrochloride tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m² is not recommended.

In patients taking rosiglitazone maleate and metformin hydrochloride tablets whose eGFR later falls below 45 mL/minute/1.73 m², assess the benefit risk of continuing therapy.
Discontinue rosiglitazone maleate and metformin hydrochloride tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m² [see Contraindications (4), Warnings and Precautions (5.1)].

**Hepatic Impairment:** Liver enzymes should be measured prior to initiating treatment with rosiglitazone maleate and metformin hydrochloride tablets. Therapy with rosiglitazone maleate and metformin hydrochloride tablets should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT > 2.5X upper limit of normal at start of therapy). After initiation of rosiglitazone maleate and metformin hydrochloride tablets, liver enzymes should be monitored periodically per the clinical judgment of the healthcare professional [see Warnings and Precautions (5.6), Clinical Pharmacology (12.3)]. Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Rosiglitazone maleate and metformin hydrochloride tablets are not recommended in patients with hepatic impairment [see Warnings and Precautions (5.1)].

**Geriatric:** The initial and maintenance dosing of rosiglitazone maleate and metformin hydrochloride tablets should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Assess renal function more frequently in elderly patients [see Warnings and Precautions (5.1)].

**Pediatric:** Safety and effectiveness of rosiglitazone maleate and metformin hydrochloride tablets in pediatric patients have not been established. Rosiglitazone maleate and metformin hydrochloride tablets and rosiglitazone are not recommended for use in pediatric patients.

**Pregnancy:** Rosiglitazone maleate and metformin hydrochloride tablets are not recommended for use in pregnancy.

### 2.5 Discontinuation for Iodinated Contrast Imaging Procedures

Discontinue rosiglitazone maleate and metformin hydrochloride tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/minute/1.73 m²; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart rosiglitazone maleate and metformin hydrochloride tablets if renal function is stable [see Warnings and Precautions (5.1)].

### 3 DOSAGE FORMS AND STRENGTHS

Rosiglitazone maleate and metformin hydrochloride tablets are available as follows:

- 1 mg/500 mg – yellow, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7530” on the other in bottles of 60 and 100.
- 2 mg/500 mg – light-pink, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7531” on the other in bottles of 60, 100, and 500.
- 4 mg/500 mg – orange, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7532” on the other in bottles of 60, 100, and 500.
- 2 mg/1,000 mg – yellow, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7533” on the other in bottles of 60 and 100.
- 4 mg/1,000 mg – pink, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7534” on the other in bottles of 60 and 100.

### 4 CONTRAINDICATIONS

- Initiation in patients with established New York Heart Association (NYHA) Class III or IV heart failure [see Boxed Warning].
- Severe renal impairment (eGFR below 30 mL/minute/1.73 m²).
- Use in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
- Use in patients with a history of a hypersensitivity reaction to rosiglitazone or any of the product’s ingredients.
5 WARNINGS AND PRECAUTIONS

5.1 Lactic Acidosis

There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension, and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (> 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate:pyruvate ratio; metformin plasma levels generally > 5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.

If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of rosiglitazone maleate and metformin hydrochloride tablets. In patients treated with rosiglitazone maleate and metformin hydrochloride tablets with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable, with a clearance of up to 170 mL/minute under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.

Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue rosiglitazone maleate and metformin hydrochloride tablets and report these symptoms to their healthcare provider.

For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:

Renal Impairment: The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment. The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient’s renal function include [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)]:

- Before initiating rosiglitazone maleate and metformin hydrochloride tablets, obtain an eGFR.
- Rosiglitazone maleate and metformin hydrochloride tablets are contraindicated in patients with an eGFR less than 30 mL/minute/1.73 m² [see Contraindications (4)].
- Initiation of rosiglitazone maleate and metformin hydrochloride tablets is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m².
- Obtain an eGFR at least annually in all patients taking rosiglitazone maleate and metformin hydrochloride tablets. In patients at increased risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.
- In patients taking rosiglitazone maleate and metformin hydrochloride tablets whose eGFR later falls below 45 mL/minute/1.73 m², assess the benefit and risk of continuing therapy.

Drug Interactions: The concomitant use of rosiglitazone maleate and metformin hydrochloride tablets with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation [see Drug Interactions (7)]. Therefore, consider more frequent monitoring of patients.

Age 65 or Greater: The risk of metformin-associated lactic acidosis increases with the patient’s age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients [see Use in Specific Populations (8.5)].
**Radiological Studies with Contrast:** Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop rosiglitazone maleate and metformin hydrochloride tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/minute/1.73 m²; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart rosiglitazone maleate and metformin hydrochloride tablets if renal function is stable.

**Surgery and Other Procedures:** Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. Rosiglitazone maleate and metformin hydrochloride tablets should be temporarily discontinued while patients have restricted food and fluid intake.

**Hypoxic States:** Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur, discontinue rosiglitazone maleate and metformin hydrochloride tablets.

**Excessive Alcohol Intake:** Alcohol potentiates the effect of metformin on lactate metabolism and this may increase the risk of metformin-associated lactic acidosis. Warn patients against excessive alcohol intake while receiving rosiglitazone maleate and metformin hydrochloride tablets.

**Hepatic Impairment:** Patients with hepatic impairment have developed metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of rosiglitazone maleate and metformin hydrochloride tablets in patients with clinical or laboratory evidence of hepatic disease.

### 5.2 Cardiac Failure

Rosiglitazone, like other thiazolidinediones, alone or in combination with other antidiabetic agents, can cause fluid retention, which may exacerbate or lead to heart failure. Patients should be observed for signs and symptoms of heart failure. If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of rosiglitazone must be considered [see Boxed Warning].

Patients with congestive heart failure (CHF) NYHA Class I and II treated with rosiglitazone have an increased risk of cardiovascular events. A 52 week, double-blind, placebo-controlled, echocardiographic trial was conducted in 224 patients with type 2 diabetes mellitus and NYHA Class I or II CHF (ejection fraction ≤ 45%) on background antidiabetic and CHF therapy. An independent committee conducted a blinded evaluation of fluid-related events (including congestive heart failure) and cardiovascular hospitalizations according to predefined criteria (adjudication). Separate from the adjudication, other cardiovascular adverse events were reported by investigators. Although no treatment difference in change from baseline of ejection fractions was observed, more cardiovascular adverse events were observed with rosiglitazone treatment compared with placebo during the 52 week trial (see Table 2).

#### Table 2. Emergent Cardiovascular Adverse Events in Patients With Congestive Heart Failure (NYHA Class I and II) Treated With Rosiglitazone or Placebo (in Addition to Background Antidiabetic and CHF Therapy)

<table>
<thead>
<tr>
<th>Events</th>
<th>Rosiglitazone N = 110 n (%)</th>
<th>Placebo N = 114 n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudicated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>5 (5%)</td>
<td>4 (4%)</td>
</tr>
<tr>
<td>CHF worsening</td>
<td></td>
<td></td>
</tr>
<tr>
<td>– with overnight hospitalization</td>
<td>7 (6%)</td>
<td>4 (4%)</td>
</tr>
<tr>
<td>– without overnight hospitalization</td>
<td>5 (5%)</td>
<td>4 (4%)</td>
</tr>
</tbody>
</table>
New or worsening edema | 28 (25%) | 10 (9%)
New or worsening dyspnea | 29 (26%) | 19 (17%)
Increases in CHF medication | 36 (33%) | 20 (18%)
Cardiovascular hospitalization* | 21 (19%) | 15 (13%)

**Investigator-reported, non-adjudicated**

| Ischemic adverse events | 10 (9%) | 5 (4%) |
| – Myocardial infarction | 5 (5%) | 2 (2%) |
| – Angina | 6 (5%) | 3 (3%) |

1. Includes hospitalization for any cardiovascular reason.

In a long-term, cardiovascular outcome trial (RECORD) in patients with type 2 diabetes [see Adverse Reactions (6.1)], the incidence of heart failure was higher in patients treated with rosiglitazone [2.7% (61/2,220) compared with active control 1.3% (29/2,227), HR 2.10 (95% CI: 1.35, 3.27)].

Initiation of rosiglitazone maleate and metformin hydrochloride tablets in patients with established NYHA Class III or IV heart failure is contraindicated. Rosiglitazone maleate and metformin hydrochloride tablets are not recommended in patients with symptomatic heart failure [see Boxed Warning].

Patients experiencing acute coronary syndromes have not been studied in controlled clinical trials. In view of the potential for development of heart failure in patients having an acute coronary event, initiation of rosiglitazone maleate and metformin hydrochloride tablets is not recommended for patients experiencing an acute coronary event, and discontinuation of rosiglitazone maleate and metformin hydrochloride tablets during this acute phase should be considered.

Patients with NYHA Class III and IV cardiac status (with or without CHF) have not been studied in controlled clinical trials. Rosiglitazone maleate and metformin hydrochloride tablets are not recommended in patients with NYHA Class III and IV cardiac status.

**Congestive Heart Failure During Coadministration of Rosiglitazone with Insulin:** In trials in which rosiglitazone was added to insulin, rosiglitazone increased the risk of congestive heart failure. Coadministration of rosiglitazone and insulin is not recommended [see Indications and Usage (1), Warnings and Precautions (5.3)].

In 7 controlled, randomized, double-blind trials which had durations from 16 to 26 weeks and which were included in a meta-analysis [see Warnings and Precautions (5.3)], patients with type 2 diabetes mellitus were randomized to coadministration of rosiglitazone and insulin (N = 1,018) or insulin (N = 815). In these 7 trials, rosiglitazone was added to insulin. These trials included patients with long-standing diabetes (median duration of 12 years) and a high prevalence of preexisting medical conditions, including peripheral neuropathy, retinopathy, ischemic heart disease, vascular disease, and congestive heart failure. The total number of patients with emergent congestive heart failure was 23 (2.3%) and 8 (1.0%) in the rosiglitazone plus insulin and insulin groups, respectively.

**Heart Failure in Observational Studies of Elderly Diabetic Patients Comparing Rosiglitazone with Pioglitazone:** Three observational studies in elderly diabetic patients (age 65 years and older) found that rosiglitazone statistically significantly increased the risk of hospitalized heart failure compared to use of pioglitazone. One other observational study in patients with a mean age of 54 years, which also included an analysis in a subpopulation of patients > 65 years of age, found no statistically significant increase in emergency department visits or hospitalization for heart failure in patients treated with rosiglitazone compared with pioglitazone in the older subgroup.

### 5.3 Major Adverse Cardiovascular Events

Data from long-term, prospective, randomized, controlled clinical trials of rosiglitazone versus metformin or sulfonylureas, particularly a cardiovascular outcome trial (RECORD), observed no difference in overall mortality or in major adverse cardiovascular events (MACE) and its components. A meta-analysis of mostly short-term trials suggested an increased risk for myocardial infarction with rosiglitazone compared with placebo.
Cardiovascular Events in Large, Long-term, Prospective, Randomized, Controlled Trials of Rosiglitazone: RECORD, a prospectively designed cardiovascular outcome trial (mean follow-up 5.5 years; 4,447 patients), compared the addition of rosiglitazone to metformin or a sulfonylurea (N = 2,220) with a control group of metformin plus sulfonylurea (N = 2,227) in patients with type 2 diabetes [see Adverse Reactions (6.1)]. Non-inferiority was demonstrated for the primary endpoint, cardiovascular hospitalization or cardiovascular death, for rosiglitazone compared with control [HR 0.99 (95% CI: 0.85, 1.16)] demonstrating no overall increased risk in cardiovascular morbidity or mortality. The hazard ratios for total mortality and MACE were consistent with the primary endpoint and the 95% CI similarly excluded a 20% increase in risk for rosiglitazone. The hazard ratios for the components of MACE were 0.72 (95% CI: 0.49, 1.06) for stroke, 1.14 (95% CI: 0.80, 1.63) for myocardial infarction, and 0.84 (95% CI: 0.59, 1.18) for cardiovascular death.

The results of RECORD are consistent with the findings of 2 earlier long-term, prospective, randomized, controlled clinical trials (each trial > 3 years' duration; total of 9,620 patients) (see Figure 1). In patients with impaired glucose tolerance (DREAM trial), although the incidence of cardiovascular events was higher among subjects who were randomized to rosiglitazone in combination with ramipril than among subjects randomized to ramipril alone, no statistically significant differences were observed for MACE and its components between rosiglitazone and placebo. In type 2 diabetes patients who were initiating oral agent monotherapy (ADOPT trial), no statistically significant differences were observed for MACE and its components between rosiglitazone and metformin or a sulfonylurea.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>n (%)</th>
<th>n (%)</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RECORD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSG+SU or MET vs SU+MET</td>
<td>2220</td>
<td>154 (6.9%)</td>
<td>72 (3.2%)</td>
<td>136 (6.1%)</td>
</tr>
<tr>
<td>ADOPT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSG vs SU</td>
<td>1456</td>
<td>35 (2.4%)</td>
<td>20 (1.4%)</td>
<td>12 (0.8%)</td>
</tr>
<tr>
<td>RSG vs MET</td>
<td>1441</td>
<td>28 (1.9%)</td>
<td>13 (1.0%)</td>
<td>21 (1.3%)</td>
</tr>
<tr>
<td>DREAM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSG vs Placebo</td>
<td>1325</td>
<td>15 (1.1%)</td>
<td>5 (0.4%)</td>
<td>15 (1.1%)</td>
</tr>
<tr>
<td>RSG+RAM vs RAM</td>
<td>1310</td>
<td>18 (1.4%)</td>
<td>12 (0.9%)</td>
<td>15 (1.1%)</td>
</tr>
<tr>
<td>OVERALL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSG vs control</td>
<td>7756</td>
<td>222 (3.5%)</td>
<td>108 (1.7%)</td>
<td>178 (2.8%)</td>
</tr>
</tbody>
</table>

RSG = rosiglitazone; SU = sulfonylurea; MET = metformin; RAM = ramipril
*Mycocardial infarction includes fatal and non-fatal MI plus sudden death

Figure 1. Hazard Ratios for the Risk of MACE, Myocardial Infarction, and Total Mortality With Rosiglitazone Compared With a Control Group in Long-term Trials

Cardiovascular Events in a Group of 52 Clinical Trials: In a meta-analysis of 52 double-blind, randomized, controlled clinical trials designed to assess glucose-lowering efficacy in type 2 diabetes (mean duration 6 months), a statistically significant increased risk of myocardial infarction with rosiglitazone versus pooled comparators was observed [0.4% versus 0.3%; OR 1.8, (95% CI: 1.03, 3.25)]. A statistically non-significant increased risk of MACE was observed with rosiglitazone versus pooled comparators (OR 1.44, 95% CI: 0.95, 2.20). In the placebo-controlled trials, a statistically
significant increased risk of myocardial infarction [0.4% versus 0.2%, OR 2.23 (95% CI: 1.14, 4.64)] and statistically
non-significant increased risk of MACE [0.7% versus 0.5%, OR 1.53 (95% CI: 0.94, 2.54)] with rosiglitazone were
observed. In the active-controlled trials, there was no increased risk of myocardial infarction or MACE.

Mortality in Observational Studies of Rosiglitazone Compared with Pioglitazone:
Three observational studies in elderly diabetic patients (age 65 years and older) found that rosiglitazone statistically
significantly increased the risk of all-cause mortality compared with use of pioglitazone. One observational study in
patients with a mean age of 54 years found no difference in all-cause mortality between patients treated with rosiglitazone
compared with pioglitazone and reported similar results in the subpopulation of patients > 65 years of age. One additional
small, prospective, observational study found no statistically significant differences for CV mortality and all-cause
mortality in patients treated with rosiglitazone compared with pioglitazone.

5.4 Edema
Rosiglitazone maleate and metformin hydrochloride tablets should be used with caution in patients with edema. In a
clinical trial in healthy volunteers who received rosiglitazone 8 mg once daily for 8 weeks, there was a statistically
significant increase in median plasma volume compared with placebo. Since thiazolidinediones, including rosiglitazone,
can cause fluid retention, which can exacerbate or lead to congestive heart failure, rosiglitazone maleate and metformin
hydrochloride tablets should be used with caution in patients at risk for heart failure. Patients should be monitored for
signs and symptoms of heart failure [see Boxed Warning, Warnings and Precautions (5.2, Patient Counseling
Information (17)].

In controlled clinical trials of patients with type 2 diabetes, mild to moderate edema was reported in patients treated with
rosiglitazone, and may be dose-related. Patients with ongoing edema were more likely to have adverse events associated
with edema if started on combination therapy with insulin and rosiglitazone [see Adverse Reactions (6.1)]. The use of
rosiglitazone maleate and metformin hydrochloride tablets in combination with insulin is not recommended [see Warnings
and Precautions (5.2, 5.3)].

5.5 Weight Gain
Dose-related weight gain was seen with rosiglitazone alone and rosiglitazone together with other hypoglycemic agents
(see Table 3). No overall change in median weight was observed with rosiglitazone maleate and metformin hydrochloride
in drug-naïve patients. The mechanism of weight gain with rosiglitazone is unclear but probably involves a combination
of fluid retention and fat accumulation.

**Table 3. Weight Changes (kg) From Baseline at Endpoint During Clinical Trials [Median (25th, 75th
Percentiles)]**

<table>
<thead>
<tr>
<th>Duration</th>
<th>Control Group</th>
<th>Rosiglitazone 4 mg</th>
<th>Rosiglitazone 8 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26 weeks</td>
<td>Placebo</td>
<td>-0.9 (-2.8, 0.9)</td>
<td>1.0 (0.9, 3.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N = 210</td>
<td>N = 436</td>
</tr>
<tr>
<td>52 weeks</td>
<td>Sulfonylurea</td>
<td>2.0 (0, 4.0)</td>
<td>2.0 (-0.6, 4.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N = 173</td>
<td>N = 150</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Combination Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
In a 4 to 6 year, monotherapy, comparative trial (ADOPT) in patients recently diagnosed with type 2 diabetes not previously treated with antidiabetic medication, the median weight change (25th, 75th percentiles) from baseline at 4 years was 3.5 kg (0.0, 8.1) for rosiglitazone, 2.0 kg (-1.0, 4.8) for glyburide, and -2.4 kg (-5.4, 0.5) for metformin.

In postmarketing experience with rosiglitazone alone or in combination with other hypoglycemic agents, there have been rare reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive edema and congestive heart failure [see Boxed Warning].

### 5.6 Hepatic Effects

**Rosiglitazone**: Liver enzymes should be measured prior to the initiation of therapy with rosiglitazone maleate and metformin hydrochloride in all patients and periodically thereafter per the clinical judgment of the healthcare professional. Therapy with rosiglitazone maleate and metformin hydrochloride tablets should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5X upper limit of normal). Patients with mildly elevated liver enzymes (ALT levels ≤ 2.5X upper limit of normal) at baseline or during therapy with rosiglitazone maleate and metformin hydrochloride tablets should be evaluated to determine the cause of the liver enzyme elevation. Initiation of, or continuation of, therapy with rosiglitazone maleate and metformin hydrochloride tablets in patients with mild liver enzyme elevations should

<table>
<thead>
<tr>
<th>Duration</th>
<th>Control Group</th>
<th>Rosiglitazone Maleate and Metformin Hydrochloride</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sulfonylurea</td>
<td>Rosiglitazone 4 mg</td>
</tr>
<tr>
<td>24 to 26 weeks</td>
<td>0 (-1.0, 1.3)</td>
<td>2.2 (0.5, 4.0)</td>
</tr>
<tr>
<td></td>
<td>N = 1,155</td>
<td>N = 613</td>
</tr>
<tr>
<td>26 weeks</td>
<td>Metformin</td>
<td>-1.4 (-3.2, 0.2)</td>
</tr>
<tr>
<td></td>
<td>N = 175</td>
<td>N = 100</td>
</tr>
<tr>
<td>26 weeks</td>
<td>Insulin</td>
<td>0.9 (-0.5, 2.7)</td>
</tr>
<tr>
<td></td>
<td>N = 162</td>
<td>N = 164</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration</th>
<th>Control Group</th>
<th>Rosiglitazone Maleate and Metformin Hydrochloride + Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 weeks</td>
<td>Insulin</td>
<td>2.6 kg (0.3, 4.8)</td>
</tr>
<tr>
<td></td>
<td>N = 145</td>
<td>N = 147</td>
</tr>
</tbody>
</table>
proceed with caution and include close clinical follow-up, including more frequent liver enzyme monitoring, to determine if the liver enzyme elevations resolve or worsen. If at any time ALT levels increase to > 3X the upper limit of normal in patients on therapy with rosiglitazone maleate and metformin hydrochloride tablets, liver enzyme levels should be rechecked as soon as possible. If ALT levels remain > 3X the upper limit of normal, therapy with rosiglitazone maleate and metformin hydrochloride tablets should be discontinued.

If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with rosiglitazone maleate and metformin hydrochloride tablets should be guided by clinical judgment pending laboratory evaluations. If jaundice is observed, drug therapy should be discontinued.

In addition, if the presence of hepatic disease or hepatic dysfunction of sufficient magnitude to predispose to lactic acidosis is confirmed, therapy with rosiglitazone maleate and metformin hydrochloride tablets should be discontinued.

5.7 Macular Edema

Macular edema has been reported in postmarketing experience in some diabetic patients who were taking rosiglitazone or another thiazolidinedione. Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination. Most patients had peripheral edema at the time macular edema was diagnosed. Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione. Patients with diabetes should have regular eye exams by an ophthalmologist, per the Standards of Care of the American Diabetes Association. Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient’s underlying medications or other physical findings [see Adverse Reactions (6.3)].

5.8 Fractures

Long-term trials (ADOPT and RECORD) show an increased incidence of bone fracture in patients, particularly female patients, taking rosiglitazone [see Adverse Reactions (6.1)]. This increased incidence was noted after the first year of treatment and persisted during the course of the trial. The majority of the fractures in the women who received rosiglitazone occurred in the upper arm, hand, and foot. These sites of fracture are different from those usually associated with postmenopausal osteoporosis (e.g., hip or spine). Other trials suggest that this risk may also apply to men, although the risk of fracture among women appears higher than that among men. The risk of fracture should be considered in the care of patients treated with rosiglitazone, and attention given to assessing and maintaining bone health according to current standards of care.

5.9 Hematologic Effects

Decreases in mean hemoglobin and hematocrit occurred in a dose-related fashion in adult patients treated with rosiglitazone [see Adverse Reactions (6.2)]. The observed changes may be related to the increased plasma volume observed with treatment with rosiglitazone and may be dose-related. The decrease in hemoglobin was seen more frequently in combination rosiglitazone and metformin therapy than in rosiglitazone therapy alone. Vitamin B12 deficiency may contribute to the observed reductions in hemoglobin [see Warnings and Precautions (5.10)]. Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) should be performed, at least on an annual basis.

5.10 Vitamin B12 Levels

In controlled clinical trials of metformin of 29 weeks’ duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation. Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to
developing subnormal vitamin B₁₂ levels. In these patients, routine serum vitamin B₁₂ measurements at 2 to 3 year intervals may be useful. Vitamin B₁₂ deficiency should be excluded if megaloblastic anemia is suspected [see Warnings and Precautions (5.9)].

5.11 Diabetes and Blood Glucose Control

Periodic fasting blood glucose and HbA₁c measurements should be performed to monitor therapeutic response.

When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold rosiglitazone maleate and metformin hydrochloride tablets and temporarily administer insulin. Rosiglitazone maleate and metformin hydrochloride tablets may be reinstituted after the acute episode is resolved.

Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with hypoglycemic agents (such as sulfonylureas or insulin) or ethanol. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking β-adrenergic blocking drugs.

Patients receiving rosiglitazone in combination with other hypoglycemic agents may be at risk for hypoglycemia, and a reduction in the dose of the concomitant agent may be necessary.

5.12 Ovulation

Therapy with rosiglitazone, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking rosiglitazone maleate and metformin hydrochloride tablets [see Use in Specific Populations (8.1)]. Thus, adequate contraception in premenopausal women should be recommended. This possible effect has not been specifically investigated in clinical trials; therefore, the frequency of this occurrence is not known.

Although hormonal imbalance has been seen in preclinical studies [see Nonclinical Toxicology (13.1)], the clinical significance of this finding is not known. If unexpected menstrual dysfunction occurs, the benefits of continued therapy with rosiglitazone maleate and metformin hydrochloride tablets should be reviewed.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail elsewhere in the labeling:

- Lactic Acidosis [see Warnings and Precautions (5.1)]
- Cardiac Failure [see Warnings and Precautions (5.2)]
- Major Adverse Cardiovascular Events [see Warnings and Precautions (5.3)]
- Edema [see Warnings and Precautions (5.4)]
- Weight Gain [see Warnings and Precautions (5.5)]
- Hepatic Effects [see Warnings and Precautions (5.6)]
- Macular Edema [see Warnings and Precautions (5.7)]
- Fractures [see Warnings and Precautions (5.8)]
- Hematologic Effects [see Warnings and Precautions (5.9)]
- Vitamin B₁₂ Levels [see Warnings and Precautions (5.10)]
- Ovulation [see Warnings and Precautions (5.12)]
6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Patients With Inadequate Glycemic Control on Diet and Exercise: Table 4 summarizes the incidence and types of adverse reactions without regard to causality reported in a controlled, 32 week, double-blind clinical trial of rosiglitazone maleate and metformin hydrochloride tablets in patients with inadequate glycemic control on diet and exercise (N = 468).

**Table 4. Adverse Events (≥ 5% for Rosiglitazone Maleate and Metformin Hydrochloride) Reported by Patients With Inadequate Glycemic Control on Diet and Exercise in a 32 Week, Double-blind Clinical Trial of Rosiglitazone Maleate and Metformin Hydrochloride**

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Rosiglitazone Maleate and Metformin Hydrochloride %</th>
<th>Metformin %</th>
<th>Rosiglitazone %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea/vomiting</td>
<td>16</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>14</td>
<td>21</td>
<td>7</td>
</tr>
<tr>
<td>Headache</td>
<td>11</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>10</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>9</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Dizziness</td>
<td>8</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Edema</td>
<td>6</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>6</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Loose stools</td>
<td>5</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Constipation</td>
<td>5</td>
<td>4</td>
<td>6</td>
</tr>
</tbody>
</table>

Mild (no intervention required) to moderate (minor intervention required) symptomatic hypoglycemia was reported by 12% (18/155) of patients treated with rosiglitazone maleate and metformin hydrochloride tablets, 14/154 (9%) with metformin, and 8% (13/159) with rosiglitazone. Approximately half of these episodes were accompanied by a simultaneous capillary glucose measurement, and the rate of confirmed hypoglycemia (blood glucose ≤ 50 mg/dL) was low in this clinical trial: 0.6% (1/155) for rosiglitazone maleate and metformin hydrochloride tablets, 1.3% (2/154) for metformin, and 0% with rosiglitazone. No hypoglycemic episode led to withdrawal in patients treated with rosiglitazone maleate and metformin hydrochloride tablets, and no patients required medical intervention due to hypoglycemia.

The incidence of edema was 6% on rosiglitazone maleate and metformin hydrochloride tablets compared with 7% on rosiglitazone and 3% on metformin.

The incidence of anemia was 4% in patients treated with rosiglitazone maleate and metformin hydrochloride tablets compared with either rosiglitazone (2%) or metformin (0%).

Patients Inadequately Controlled on Rosiglitazone Monotherapy: The incidence and types of adverse events reported in controlled, 26 week clinical trials of rosiglitazone administered in combination with metformin 2,500 mg/day in comparison with adverse reactions reported in association with rosiglitazone and metformin monotherapies are shown in Table 5. Overall, the types of adverse reactions without regard to causality reported when rosiglitazone was used in combination with metformin were similar to those reported during monotherapy with rosiglitazone.

**Table 5. Adverse Events (≥ 5% for Rosiglitazone Plus Metformin) Reported by Patients in 26 Week, Double-blind Clinical Trials of Rosiglitazone Added to Metformin Therapy**

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Rosiglitazone + Metformin</th>
<th>Rosiglitazone</th>
<th>Placebo</th>
<th>Metformin</th>
</tr>
</thead>
</table>


Reports of hypoglycemia in patients treated with rosiglitazone added to maximum metformin therapy in double-blind trials were more frequent (3.0%) than in patients treated with rosiglitazone (0.6%) or metformin monotherapies (1.3%) or placebo (0.2%). Overall, anemia and edema were generally mild to moderate in severity and usually did not require discontinuation of treatment with rosiglitazone.

Edema was reported in 4.8% of patients receiving rosiglitazone compared with 1.3% on placebo, and 2.2% on metformin monotherapy and 4.4% on rosiglitazone in combination with maximum doses of metformin.

Reports of anemia (7.1%) were greater in patients treated with rosiglitazone added to metformin compared with monotherapy with rosiglitazone. Lower pre-treatment hemoglobin/hematocrit levels in patients enrolled in the metformin and rosiglitazone combination therapy clinical trials may have contributed to the higher reporting rate of anemia in these trials [see Adverse Reactions (6.2)].

Combination With Insulin: The incidence of hypoglycemia (confirmed by fingerstick blood glucose concentration ≤ 50 mg/dL) was 14% for patients on rosiglitazone maleate and metformin hydrochloride tablets plus insulin compared with 10% for patients on insulin monotherapy.

The incidence of edema was 7% when insulin was added to rosiglitazone maleate and metformin hydrochloride tablets compared with 3% with insulin monotherapy. This trial excluded patients with preexisting heart failure or new or worsening edema on rosiglitazone maleate and metformin hydrochloride tablets. However, in 26 week, double-blind, fixed-dose trials of rosiglitazone added to insulin, edema was reported with higher frequency (rosiglitazone in combination with insulin, 14.7%; insulin, 5.4%) [see Warnings and Precautions (5.2)].

In trials in which rosiglitazone was added to insulin, rosiglitazone increased the risk of congestive heart failure [see Warnings and Precautions (5.2)].

In a trial in which insulin was added to rosiglitazone maleate and metformin hydrochloride tablets, no myocardial ischemia was observed in the insulin group (N = 158), and no congestive heart failure was reported in either group. There was one myocardial ischemic event and one sudden death in the group receiving rosiglitazone maleate and metformin hydrochloride plus insulin (N = 161) [see Warnings and Precautions (5.2)].

The incidence of anemia was 2% for rosiglitazone maleate and metformin hydrochloride tablets in combination with insulin compared with 1% for insulin monotherapy.

Long-term Trial of Rosiglitazone as Monotherapy: A long-term, 4 to 6 year trial (ADOPT) compared the use of rosiglitazone (n = 1,456), glyburide (n = 1,441), and metformin (n = 1,454) as monotherapy in patients recently diagnosed with type 2 diabetes who were not previously treated with antidiabetic medication. Table 6 presents adverse reactions without regard to causality; rates are expressed per 100 patient-years (PY) exposure to account for the differences in exposure to trial medication across the 3 treatment groups.
In ADOPT, fractures were reported in a greater number of women treated with rosiglitazone (9.3%, 2.7/100 patient-years) compared with glyburide (3.5%, 1.3/100 patient-years) or metformin (5.1%, 1.5/100 patient-years). The majority of the fractures in the women who received rosiglitazone were reported in the upper arm, hand, and foot [see Warnings and Precautions (5.8)]. The observed incidence of fractures for male patients was similar among the 3 treatment groups.

Table 6. On-therapy Adverse Events [≥ 5 Events/100 Patient-years (PY)] in any Treatment Group Reported in a 4 to 6 Year Clinical Trial of Rosiglitazone as Monotherapy (ADOPT)

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Rosiglitazone</th>
<th>Glyburide</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 1,456</td>
<td>N = 1,441</td>
<td>N = 1,454</td>
</tr>
<tr>
<td></td>
<td>PY = 4,954</td>
<td>PY = 4,244</td>
<td>PY = 4,906</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>6.3</td>
<td>6.9</td>
<td>6.6</td>
</tr>
<tr>
<td>Back pain</td>
<td>5.1</td>
<td>4.9</td>
<td>5.3</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5.0</td>
<td>4.8</td>
<td>4.2</td>
</tr>
<tr>
<td>Hypertension</td>
<td>4.4</td>
<td>6.0</td>
<td>6.1</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>4.3</td>
<td>5.0</td>
<td>4.7</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>2.9</td>
<td>13.0</td>
<td>3.4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2.5</td>
<td>3.2</td>
<td>6.8</td>
</tr>
</tbody>
</table>

Long-term Trial of Rosiglitazone as Combination Therapy (RECORD): RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) was a multicenter, randomized, open-label, non-inferiority trial in subjects with type 2 diabetes inadequately controlled on maximum doses of metformin or sulfonylurea (glyburide, gliclazide, or glimepiride) to compare the time to reach the combined cardiovascular endpoint of cardiovascular death or cardiovascular hospitalization between patients randomized to the addition of rosiglitazone versus metformin or sulfonylurea. The trial included patients who have failed metformin or sulfonylurea monotherapy; those who failed metformin (n = 2,222) were randomized to receive either add-on rosiglitazone (n = 1,117) or add-on sulfonylurea (n = 1,105), and those who failed sulfonylurea (n = 2,225) were randomized to receive either add-on rosiglitazone (n = 1,103) or add-on metformin (n = 1,122). Patients were treated to target HbA1c ≤ 7% throughout the trial.

The mean age of patients in this trial was 58 years, 52% were male, and the mean duration of follow-up was 5.5 years. Rosiglitazone demonstrated non-inferiority to active control for the primary endpoint of cardiovascular hospitalization or cardiovascular death (HR 0.99, 95% CI: 0.85 to 1.16). There were no significant differences between groups for secondary endpoints with the exception of congestive heart failure (see Table 7). The incidence of congestive heart failure was significantly greater among patients randomized to rosiglitazone.

Table 7. Cardiovascular (CV) Outcomes for the RECORD Trial

<table>
<thead>
<tr>
<th>Primary Endpoint</th>
<th>Rosiglitazone</th>
<th>Active Control</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CV death or CV hospitalization</td>
<td>321</td>
<td>323</td>
<td>0.99</td>
<td>0.85 to 1.16</td>
</tr>
</tbody>
</table>

Secondary Endpoint

| All-cause death                         | 136           | 157            | 0.86         | 0.68 to 1.08    |
| CV death                                | 60            | 71             | 0.84         | 0.59 to 1.18    |
| Myocardial infarction                   | 64            | 56             | 1.14         | 0.80 to 1.63    |
| Stroke                                  | 46            | 63             | 0.72         | 0.49 to 1.06    |
| CV death, myocardial infarction, or stroke| 154          | 165            | 0.93         | 0.74 to 1.15    |
| Heart failure                           | 61            | 29             | 2.10         | 1.35 to 3.27    |

There was an increased incidence of bone fracture for subjects randomized to rosiglitazone in addition to metformin or sulfonylurea compared with those randomized to metformin plus sulfonylurea (8.3% versus 5.3%) [see Warnings and Precautions (5.8)]. The majority of fractures were reported in the upper limbs and distal lower limbs. The risk of fracture appeared to be higher in females relative to control (11.5% versus 6.3%), than in males relative to control (5.3% versus...
4.3%). Additional data are necessary to determine whether there is an increased risk of fracture in males after a longer period of follow-up.

6.2 Laboratory Abnormalities

**Hematologic:** Decreases in mean hemoglobin and hematocrit occurred in a dose-related fashion in adult patients treated with rosiglitazone (mean decreases in individual trials as much as 1.0 gram/dL hemoglobin and as much as 3.3% hematocrit). The changes occurred primarily during the first 3 months following initiation of rosiglitazone therapy or following an increase in rosiglitazone dose. The time course and magnitude of decreases were similar in patients treated with a combination of rosiglitazone and other hypoglycemic agents or monotherapy with rosiglitazone. Pre-treatment levels of hemoglobin and hematocrit were lower in patients in metformin combination trials and may have contributed to the higher reporting rate of anemia. In a single trial in pediatric patients, decreases in hemoglobin and hematocrit (mean decreases of 0.29 g/dL and 0.95%, respectively) were reported with rosiglitazone. White blood cell counts also decreased slightly in adult patients treated with rosiglitazone. Decreases in hematologic parameters may be related to increased plasma volume observed with rosiglitazone treatment.

In controlled clinical trials of metformin of 29 weeks’ duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such a decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation.

**Lipids:** Changes in serum lipids have been observed following treatment with rosiglitazone in adults [see Clinical Pharmacology (12.2)].

**Serum Transaminase Levels:** In pre-approval clinical trials in 4,598 patients treated with rosiglitazone encompassing approximately 3,600 patient-years of exposure, and in a long-term 4 to 6 year trial in 1,456 patients treated with rosiglitazone (4,954 patient-years exposure), there was no evidence of drug-induced hepatotoxicity.

In pre-approval controlled trials, 0.2% of patients treated with rosiglitazone had reversible elevations in ALT > 3X the upper limit of normal compared with 0.2% on placebo and 0.5% on active comparators. The ALT elevations in patients treated with rosiglitazone were reversible. Hyperbilirubinemia was found in 0.3% of patients treated with rosiglitazone compared with 0.9% treated with placebo and 1% in patients treated with active comparators. In pre-approval clinical trials, there were no cases of idiosyncratic drug reactions leading to hepatic failure [see Warnings and Precautions (5.6)].

In the 4 to 6 year ADOPT trial, patients treated with rosiglitazone (4,954 patient-years exposure), glyburide (4,244 patient-years exposure), or metformin (4,906 patient-years exposure) as monotherapy, had the same rate of ALT increase to > 3X upper limit of normal (0.3 per 100 patient-years exposure).

In the RECORD trial, patients randomized to rosiglitazone in addition to metformin or sulfonylurea (10,849 patient-years exposure) and to metformin plus sulfonylurea (10,209 patient-years exposure) had a rate of ALT increase to ≥ 3X upper limit of normal of approximately 0.2 and 0.3 per 100 patient-years exposure, respectively.

6.3 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of rosiglitazone maleate and metformin hydrochloride or its individual components. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.

In patients receiving thiazolidinedione therapy, serious adverse events with or without a fatal outcome, potentially related to volume expansion (e.g., congestive heart failure, pulmonary edema, and pleural effusions) have been reported [see Boxed Warning, Warnings and Precautions (5.2)].
There are postmarketing reports with rosiglitazone of hepatitis, hepatic enzyme elevations to 3 or more times the upper limit of normal, and hepatic failure with and without fatal outcome, although causality has not been established.

There are postmarketing reports with rosiglitazone of rash, pruritus, urticaria, angioedema, anaphylactic reaction, Stevens-Johnson syndrome [see Contraindications (4)], and new onset or worsening diabetic macular edema with decreased visual acuity [see Warnings and Precautions (5.7)].

Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin (See also GLUCOPHAGE® prescribing information).

7 DRUG INTERACTIONS

7.1 Drugs Metabolized by Cytochrome P450
An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response [see Clinical Pharmacology (12.4)].

7.2 Drugs That Reduce Metformin Clearance
Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] /multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Consider the benefits and risks of concomitant use.

7.3 Carbonic Anhydrase Inhibitors
Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide, or dichlorphenamide) frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with rosiglitazone maleate and metformin hydrochloride may increase the risk for lactic acidosis [see Warnings and Precautions (5.1), Clinical Pharmacology (12.4)]. Consider more frequent monitoring of these patients.

7.4 Alcohol
Alcohol is known to potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake while receiving rosiglitazone maleate and metformin hydrochloride.

7.5 Drugs That Produce Hyperglycemia
When drugs that produce hyperglycemia, which may lead to loss of glycemic control, are administered to a patient receiving rosiglitazone maleate and metformin hydrochloride, the patient should be closely observed to maintain adequate glycemic control [see Clinical Pharmacology (12.4)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Pregnancy category C.

All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. Careful monitoring of glucose control is essential in such patients. Most experts recommend that insulin monotherapy be used during pregnancy to maintain blood glucose levels as close to
normal as possible. Rosiglitazone maleate and metformin hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Human Data:** There are no adequate and well-controlled trials with rosiglitazone maleate and metformin hydrochloride or its individual components in pregnant women. Rosiglitazone has been reported to cross the human placenta and be detectable in fetal tissue. The clinical significance of these findings is unknown.

**Animal Studies:** No animal studies have been performed with rosiglitazone maleate and metformin hydrochloride. The following data are based on findings in studies performed with rosiglitazone or metformin individually.

**Rosiglitazone:** There was no effect on implantation or the embryo with rosiglitazone treatment during early pregnancy in rats, but treatment during mid-late gestation was associated with fetal death and growth retardation in both rats and rabbits. Teratogenicity was not observed at doses up to 3 mg/kg in rats and 100 mg/kg in rabbits (approximately 20 and 75 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride, respectively). Rosiglitazone caused placental pathology in rats (3 mg/kg/day). Treatment of rats during gestation through lactation reduced litter size, neonatal viability, and postnatal growth, with growth retardation reversible after puberty. For effects on the placenta, embryo/fetus, and offspring, the no-effect dose was 0.2 mg/kg/day in rats and 15 mg/kg/day in rabbits. These no-effect levels are approximately 4 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride. Rosiglitazone reduced the number of uterine implantations and live offspring when juvenile female rats were treated at 40 mg/kg/day from 27 days of age through to sexual maturity (approximately 68 times human AUC at the maximum recommended daily dose). The no-effect level was 2 mg/kg/day (approximately 4 times human AUC at the maximum recommended daily dose). There was no effect on pre- or post-natal survival or growth.

**Metformin:** Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

### 8.2 Labor and Delivery

The effect of rosiglitazone maleate and metformin hydrochloride or its components on labor and delivery in humans is unknown.

### 8.3 Nursing Mothers

No studies have been conducted with rosiglitazone maleate and metformin hydrochloride. In studies performed with the individual components, both rosiglitazone-related material and metformin were detectable in milk from lactating rats. It is not known whether rosiglitazone or metformin is excreted in human milk. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue rosiglitazone maleate and metformin hydrochloride, taking into account the importance of the drug to the mother.

### 8.4 Pediatric Use

Safety and effectiveness of rosiglitazone maleate and metformin hydrochloride in pediatric patients have not been established. Rosiglitazone maleate and metformin hydrochloride and rosiglitazone are not indicated for use in pediatric patients.

### 8.5 Geriatric Use

Because reduced renal function is associated with increasing age, rosiglitazone maleate and metformin hydrochloride should be used with caution in elderly patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see Warnings and Precautions (5.1)].

8.6 Renal Impairment

Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Rosiglitazone maleate and metformin hydrochloride is contraindicated in severe renal impairment, patients with an eGFR below 30 mL/minute/1.73 m² [see Dosage and Administration (2.4), Contraindications (4), Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Rosiglitazone maleate and metformin hydrochloride is not recommended in patients with hepatic impairment [see Warnings and Precautions (5.1)].

10 OVERDOSAGE

**Rosiglitazone:** Limited data are available with regard to overdosage in humans. In clinical trials in volunteers, rosiglitazone has been administered at single oral doses of up to 20 mg and was well tolerated. In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.

**Metformin:** Hypoglycemia has not been seen with ingestion of up to 85 grams of metformin, although lactic acidosis has occurred in such circumstances [see Warnings and Precautions (5.1)]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated metformin from patients in whom metformin overdosage is suspected.

11 DESCRIPTION

Rosiglitazone maleate and metformin hydrochloride tablets contain 2 oral antidiabetic drugs: rosiglitazone maleate and metformin hydrochloride.

Rosiglitazone maleate is an oral antidiabetic agent, which acts primarily by increasing insulin sensitivity. Rosiglitazone improves glycemic control while reducing circulating insulin levels. Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors. Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl][methyl]-2,4-thiazolidinedione, (Z)-2-butenedioate (1:1). The molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. Rosiglitazone maleate is a white to off-white solid with a melting point range of 122° to 123°C. The pKₐ values of rosiglitazone maleate are 6.8 and 6.1. It is readily soluble in ethanol and a buffered aqueous solution with pH of 2.3; solubility decreases with increasing pH in the physiological range. The structural formula of rosiglitazone maleate is:

![Structural formula of rosiglitazone maleate](image)

C₁₈H₁₉N₃O₃S•C₄H₄O₄ M.W. 473.52 (357.44 free base)

Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antidiabetic agents. Metformin hydrochloride is a white to off-white crystalline compound. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether,
and chloroform. The pKₐ of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula of metformin hydrochloride is:

![Structural formula of metformin hydrochloride]

C₄H₁₁N₅•HCl       M.W. 165.63

Rosiglitazone maleate and metformin hydrochloride tablets are available for oral administration as film-covered tablets containing rosiglitazone maleate and metformin hydrochloride equivalent to: 1 mg rosiglitazone with 500 mg metformin hydrochloride (1 mg/500 mg), 2 mg rosiglitazone with 500 mg metformin hydrochloride (2 mg/500 mg), 4 mg rosiglitazone with 500 mg metformin hydrochloride (4 mg/500 mg), 2 mg rosiglitazone with 1,000 mg metformin hydrochloride (2 mg/1,000 mg), and 4 mg rosiglitazone with 1,000 mg metformin hydrochloride (4 mg/1,000 mg). In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, and titanium dioxide. Additionally, 1 mg/500 mg tablets contain iron oxide yellow, 2 mg/500 mg tablets contain iron oxide red, 4 mg/500 mg tablets contain iron oxide red and iron oxide yellow, 2 mg/1,000 mg tablets contain iron oxide yellow, 4 mg/1,000 mg tablets contain iron oxide black and iron oxide red.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Rosiglitazone maleate and metformin hydrochloride: Rosiglitazone maleate and metformin hydrochloride combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: Rosiglitazone, a member of the thiazolidinedione class, and metformin, a member of the biguanide class. Thiazolidinediones are insulin sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas biguanides act primarily by decreasing endogenous hepatic glucose production.

Rosiglitazone: Rosiglitazone improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator–activated receptor-gamma (PPARγ). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPARγ-responsive genes also participate in the regulation of fatty acid metabolism.

Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes. The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues. Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.

In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin's action in the liver, muscle, and adipose tissue. Pharmacologic studies in animal models indicate that rosiglitazone improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.
**Metformin:** Metformin is an antidiabetic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antidiabetic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects except in special circumstances [see Warnings and Precautions (5.11)] and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

### 12.2 Pharmacodynamics

In all 26 week controlled trials, across the recommended dose range, rosiglitazone as monotherapy was associated with increases in total cholesterol, LDL-cholesterol, and HDL-cholesterol and decreases in free fatty acids.

The lipid profiles of rosiglitazone maleate and metformin hydrochloride as well as rosiglitazone and metformin monotherapies in patients who have inadequate glycemic control on diet and exercise are shown in Table 8.

**Table 8. Summary of Mean Lipid Changes in a 32 Week Trial of Rosiglitazone Maleate and Metformin Hydrochloride in Patients With Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Diet and Exercise**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Rosiglitazone Maleate and Metformin Hydrochloride N² = 132</th>
<th>Rosiglitazone N² = 128</th>
<th>Metformin N² = 117</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>200.4</td>
<td>198.4</td>
<td>201.6</td>
</tr>
<tr>
<td>% Change from baseline (mean)</td>
<td>-2.2%</td>
<td>5.3%</td>
<td>-9.0%</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>113.8</td>
<td>114.6</td>
<td>116.0</td>
</tr>
<tr>
<td>% Change from baseline (mean)</td>
<td>-0.2%</td>
<td>4.5%</td>
<td>-10.7%</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>42.6</td>
<td>42.8</td>
<td>42.9</td>
</tr>
<tr>
<td>% Change from baseline (mean)</td>
<td>5.8%</td>
<td>3.1%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>180.3</td>
<td>166.6</td>
<td>175.7</td>
</tr>
<tr>
<td>% Change from baseline (mean)</td>
<td>-18.7%</td>
<td>-4.8%</td>
<td>-15.4%</td>
</tr>
</tbody>
</table>

1. Data presented as geometric means throughout table.
2. N = Number of subjects with a baseline and end of treatment value.

The pattern of LDL, HDL, and total cholesterol changes following therapy with rosiglitazone added to metformin was generally similar to those seen with rosiglitazone monotherapy, and a small decrease in mean triglycerides was observed with the combination therapy.

### 12.3 Pharmacokinetics

**Absorption:** Rosiglitazone Maleate and Metformin Hydrochloride: In a bioequivalence and dose-proportionality trial of rosiglitazone maleate and metformin hydrochloride 4 mg/500 mg, both the rosiglitazone component and the metformin component were bioequivalent to coadministered 4 mg rosiglitazone tablet and 500 mg metformin tablet under fasted conditions (see Table 9). In this trial, dose proportionality of rosiglitazone in the combination formulations of 1 mg/500 mg and 4 mg/500 mg was demonstrated.
### Table 9. Mean (SD) Pharmacokinetic Parameters for Rosiglitazone and Metformin

<table>
<thead>
<tr>
<th>Regimen</th>
<th>N</th>
<th>Pharmacokinetic Parameter</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AUC$_{0\text{-inf}}$ (ng·h/mL)</td>
<td>$C_{\text{max}}$ (ng/mL)</td>
<td>$T_{\text{max}}$ (h)</td>
<td>$t_{\frac{1}{2}}$ (h)</td>
<td></td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>25</td>
<td>1,442 (324)</td>
<td>242 (70)</td>
<td>0.95 (0.48 to 2.47)</td>
<td>4.26 (1.18)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>25</td>
<td>1,398 (340)</td>
<td>254 (69)</td>
<td>0.57 (0.43 to 2.58)</td>
<td>3.95 (0.81)</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>24</td>
<td>349 (91)</td>
<td>63.0 (15.0)</td>
<td>0.57 (0.47 to 1.45)</td>
<td>3.87 (0.88)</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>25</td>
<td>7,116 (2,096)</td>
<td>1,106 (329)</td>
<td>2.97 (1.02 to 4.02)</td>
<td>3.46 (0.96)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>25</td>
<td>7,413 (1,838)</td>
<td>1,135 (253)</td>
<td>2.50 (1.03 to 3.98)</td>
<td>3.36 (0.54)</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>24</td>
<td>6,945 (2,045)</td>
<td>1,080 (327)</td>
<td>2.97 (1.00 to 5.98)</td>
<td>3.35 (0.59)</td>
<td></td>
</tr>
</tbody>
</table>

1. Median and range presented for $T_{\text{max}}$.

AUC = Area under the curve; $C_{\text{max}}$ = Maximum concentration; $t_{\frac{1}{2}}$ = Terminal half-life.

Regimen A = 4 mg/500 mg rosiglitazone maleate and metformin hydrochloride; Regimen B = 4 mg rosiglitazone tablet + 500 mg metformin tablet; Regimen C = 1 mg/500 mg rosiglitazone maleate and metformin hydrochloride.

Administration of rosiglitazone maleate and metformin hydrochloride 4 mg/500 mg with food resulted in no change in overall exposure (AUC) for either rosiglitazone or metformin. However, there were decreases in $C_{\text{max}}$ of both components (22% for rosiglitazone and 15% for metformin, respectively) and a delay in $T_{\text{max}}$ of both components (1.5 hours for rosiglitazone and 0.5 hours for metformin, respectively). These changes are not likely to be clinically significant. The pharmacokinetics of both the rosiglitazone component and the metformin component of rosiglitazone maleate and metformin hydrochloride when taken with food were similar to the pharmacokinetics of rosiglitazone and metformin when administered concomitantly as separate tablets with food.

**Absorption:** *Rosiglitazone:* The absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Maximum plasma concentration ($C_{\text{max}}$) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range.

**Absorption:** *Metformin:* The absolute bioavailability of a 500 mg metformin tablet given under fasting conditions is approximately 50% to 60%. Trials using single oral doses of metformin tablets of 500 mg to 1,500 mg, and 850 mg to 2,550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination.

**Distribution:** *Rosiglitazone:* The mean (CV%) oral volume of distribution ($V_{ss}/F$) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.

**Distribution:** *Metformin:* The apparent volume of distribution ($V/F$) of metformin following single oral doses of 850 mg metformin averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally < 1 mcg/mL. During controlled clinical trials, maximum metformin plasma levels did not exceed 5 mcg/mL, even at maximum doses.
Metabolism and Excretion: Rosiglitazone: Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine. The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone. In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway. Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively. The plasma half-life of [14C]related material ranged from 103 to 158 hours. The elimination half-life is 3 to 4 hours and is independent of dose.

Metabolism and Excretion: Metformin: Intravenous single-dose trials in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Renal clearance is approximately 3.5 times greater than creatinine clearance which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Specific Populations: Renal Impairment: In subjects with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [see Dosage and Administration (2.2), Contraindications (4), and Warnings and Precautions (5.1)].

Hepatic Impairment: Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared with healthy subjects. As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively. Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared with healthy subjects.

Therapy with rosiglitazone maleate and metformin hydrochloride tablets should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT > 2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].

No pharmacokinetic trials of metformin have been conducted in subjects with hepatic insufficiency.

Geriatric: Results of the population pharmacokinetics analysis (N = 716 < 65 years; N = 331 ≥ 65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone. However, limited data from controlled pharmacokinetic trials of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared with healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function [see Use in Specific Populations (8.5)].

Gender: Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (N = 405) was approximately 6% lower compared with male patients of the same body weight (N = 642). In rosiglitazone and metformin combination trials, efficacy was demonstrated with no gender differences in glycemic response.

Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analyzed according to gender (males = 19, females = 16). Similarly, in controlled clinical trials in patients with type 2 diabetes, the antihyperglycemic effect of metformin tablets was comparable in males and females.

Race: Results of a population pharmacokinetic analysis including subjects of white, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.
No trials of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical trials of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (N = 249), blacks (N = 51), and Hispanics (N = 24).

**Pediatric:** No pharmacokinetic data from trials in pediatric subjects are available for rosiglitazone maleate and metformin hydrochloride.

### 12.4 Drug-drug Interactions

**Rosiglitazone:** Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450: In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations. In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9 [see Drug Interactions (7.1)].

Rosiglitazone (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.

**Gemfibrozil:** Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared with the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].

**Rifampin:** Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared with the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].

**Metformin:** Cationic Drugs: Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction trials, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose trial. Metformin had no effect on cimetidine pharmacokinetics [see Warnings and Precautions (5.1), Drug Interactions (7.2)].

**Furosemide:** A single-dose, metformin-furosemide drug interaction trial in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood C\textsubscript{max} by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the C\textsubscript{max} and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when coadministered chronically.

**Nifedipine:** A single-dose, metformin-nifedipine drug interaction trial in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma metformin C\textsubscript{max} and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. T\textsubscript{max} and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

**Other:** Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.

In healthy volunteers, the pharmacokinetics of metformin and propranolol and metformin and ibuprofen were not affected when coadministered in single-dose interaction trials.
Metformin is negligibly bound to plasma proteins and is therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal studies have been conducted with rosiglitazone maleate and metformin hydrochloride. The following data are based on findings in studies performed with rosiglitazone or metformin individually.

Rosiglitazone: A 2 year carcinogenicity study was conducted in Charles River CD-1 mice at doses of 0.4, 1.5, and 6 mg/kg/day in the diet (highest dose equivalent to approximately 12 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride). Sprague-Dawley rats were dosed for 2 years by oral gavage at doses of 0.05, 0.3, and 2 mg/kg/day (highest dose equivalent to approximately 10 and 20 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride for male and female rats, respectively).

Rosiglitazone was not carcinogenic in the mouse. There was an increase in incidence of adipose hyperplasia in the mouse at doses ≥ 1.5 mg/kg/day (approximately 2 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride). In rats, there was a significant increase in the incidence of benign adipose tissue tumors (lipomas) at doses ≥ 0.3 mg/kg/day (approximately 2 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride). These proliferative changes in both species are considered due to the persistent pharmacological overstimulation of adipose tissue.

Rosiglitazone was not mutagenic or clastogenic in the in vitro bacterial assays for gene mutation, the in vitro chromosome aberration test in human lymphocytes, the in vivo mouse micronucleus test, and the in vivo/in vitro rat UDS assay. There was a small (about 2 fold) increase in mutation in the in vitro mouse lymphoma assay in the presence of metabolic activation.

Rosiglitazone had no effects on mating or fertility of male rats given up to 40 mg/kg/day (approximately 116 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride). Rosiglitazone altered estrous cyclicity (2 mg/kg/day) and reduced fertility (40 mg/kg/day) of female rats in association with lower plasma levels of progesterone and estradiol (approximately 20 and 200 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride, respectively). No such effects were noted at 0.2 mg/kg/day (approximately 3 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride). In juvenile rats dosed from 27 days of age through to sexual maturity (at up to 40 mg/kg/day), there was no effect on male reproductive performance, or on estrous cyclicity, mating performance or pregnancy incidence in females (approximately 68 times human AUC at the maximum recommended daily dose of rosiglitazone). In monkeys, rosiglitazone (0.6 and 4.6 mg/kg/day; approximately 3 and 15 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride, respectively) diminished the follicular phase rise in serum estradiol with consequential reduction in the luteinizing hormone surge, lower luteal phase progesterone levels, and amenorrhea. The mechanism for these effects appears to be direct inhibition of ovarian steroidogenesis.

Metformin: Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1,500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum recommended human daily dose of 2,000 mg of the metformin component of rosiglitazone maleate and metformin hydrochloride based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential.
observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.

There was no evidence of mutagenic potential of metformin in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative.

Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose of the metformin component of rosiglitazone maleate and metformin hydrochloride based on body surface area comparisons.

13.2 Animal Toxicology

Heart weights were increased in mice (3 mg/kg/day), rats (5 mg/kg/day), and dogs (2 mg/kg/day) with rosiglitazone treatments (approximately 5, 22, and 2 times human AUC at the maximum recommended human daily dose of the rosiglitazone component of rosiglitazone maleate and metformin hydrochloride, respectively). Effects in juvenile rats were consistent with those seen in adults. Morphometric measurement indicated that there was hypertrophy in cardiac ventricular tissues, which may be due to increased heart work as a result of plasma volume expansion.

14 CLINICAL STUDIES

14.1 Patients Who Have Inadequate Glycemic Control on Diet and Exercise

In a 32 week, randomized, double-blind clinical trial, 468 patients with type 2 diabetes mellitus inadequately controlled on diet and exercise alone (mean baseline FPG 198 mg/dL and mean baseline HbA1c 8.8%) were randomized to rosiglitazone maleate and metformin hydrochloride 2 mg/500 mg, rosiglitazone 4 mg, or metformin 500 mg. Doses were increased at 4 week intervals up to a maximum of 8 mg/2,000 mg for rosiglitazone maleate and metformin hydrochloride, 8 mg for rosiglitazone, and 2,000 mg for metformin to reach a target mean daily glucose of ≤ 110 mg/dL. Following the initial dosage level, rosiglitazone maleate and metformin hydrochloride, rosiglitazone, and metformin were all administered as twice-daily regimens. Statistically significant improvements in FPG and HbA1c were observed in patients treated with rosiglitazone maleate and metformin hydrochloride compared with either rosiglitazone or metformin alone (see Table 10). However, when considering the choice of therapy for drug-naïve patients, the risk-benefit of initiating monotherapy or dual therapy should be considered.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Rosiglitazone Maleate and Metformin Hydrochloride</th>
<th>Rosiglitazone</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Final Dose</td>
<td>7.2 mg/1,799 mg</td>
<td>7.7 mg</td>
<td>1,847 mg</td>
</tr>
<tr>
<td>N</td>
<td>152</td>
<td>155</td>
<td>150</td>
</tr>
<tr>
<td>FPG (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>201</td>
<td>194</td>
<td>199</td>
</tr>
<tr>
<td>Change from baseline (mean)</td>
<td>-74</td>
<td>-47</td>
<td>-51</td>
</tr>
<tr>
<td>Difference between rosiglitazone maleate and metformin hydrochloride tablets and monotherapy (adjusted mean)</td>
<td>-22</td>
<td>-22</td>
<td>-22</td>
</tr>
<tr>
<td>% of patients with ≥ 30 mg/dL decrease from baseline</td>
<td>86%</td>
<td>68%</td>
<td>64%</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.9%</td>
<td>8.8%</td>
<td>8.8%</td>
</tr>
<tr>
<td>Change from baseline (mean)</td>
<td>-2.3%</td>
<td>-1.6%</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Difference between rosiglitazone maleate and metformin hydrochloride tablets and monotherapy (adjusted mean)</td>
<td>-0.6</td>
<td>-0.4</td>
<td>-0.4</td>
</tr>
</tbody>
</table>
% of patients with HbA1c ≥ 0.7% decrease from baseline | 92% | 79% | 84%
% of Patients with HbA1c < 7.0% | 77% | 58% | 57%

1. P < 0.001 rosiglitazone maleate and metformin hydrochloride compared with rosiglitazone or metformin.

Patients screened in the double-blind clinical trial described above with HbA1c > 11% or FPG > 270 mg/dL were not eligible for blinded treatment but were treated with open-label rosiglitazone maleate and metformin hydrochloride (4 mg/1,000 mg up to a maximum dose of 8 mg/2,000 mg). Treatment with rosiglitazone maleate and metformin hydrochloride reduced mean HbA1c from a baseline of 11.8% to 7.8% and mean FPG from a baseline of 305 mg/dL to 166 mg/dL. Given the lack of direct comparators in this evaluation, determination of the exact contribution of rosiglitazone and metformin as well as diet and exercise, to the observed improvement in glycemic control is not possible.

14.2 Patients Previously Treated With Metformin

Rosiglitazone maleate and metformin hydrochloride was not studied in patients previously treated with metformin monotherapy; however, the combination of rosiglitazone and metformin was compared with rosiglitazone and metformin monotherapies in clinical trials. Bioequivalence between rosiglitazone maleate and metformin hydrochloride and coadministered rosiglitazone tablets and metformin tablets has been demonstrated [see Clinical Pharmacology (12.3)].

A total of 670 patients with type 2 diabetes participated in two 26 week, randomized, double-blind, placebo/active-controlled trials designed to assess the efficacy of rosiglitazone in combination with metformin. Rosiglitazone, administered in either once-daily or twice-daily dosing regimens, was added to the therapy of patients who were inadequately controlled on 2.5 grams/day of metformin.

In one trial, patients inadequately controlled on 2.5 grams/day of metformin (mean baseline FPG 216 mg/dL and mean baseline HbA1c 8.8%) were randomized to receive rosiglitazone 4 mg once daily, rosiglitazone 8 mg once daily, or placebo in addition to metformin. A statistically significant improvement in FPG and HbA1c was observed in patients treated with the combinations of metformin and rosiglitazone 4 mg once daily and rosiglitazone 8 mg once daily, versus patients continued on metformin alone (see Table 11).

Table 11. Glycemic Parameters in a 26 Week Trial of Rosiglitazone Added to Metformin Therapy

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Metformin</th>
<th>Rosiglitazone 4 mg Once Daily + Metformin</th>
<th>Rosiglitazone 8 mg Once Daily + Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>113</td>
<td>116</td>
<td>110</td>
</tr>
<tr>
<td>FPG (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>214</td>
<td>215</td>
<td>220</td>
</tr>
<tr>
<td>Change from baseline (mean)</td>
<td>6</td>
<td>-33</td>
<td>-48</td>
</tr>
<tr>
<td>Difference from metformin alone (adjusted mean)</td>
<td></td>
<td>-40\textsuperscript{t}</td>
<td>-53\textsuperscript{t}</td>
</tr>
<tr>
<td>% of patients with ≥ 30 mg/dL decrease from baseline</td>
<td>20%</td>
<td>45%</td>
<td>61%</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.6</td>
<td>8.9</td>
<td>8.9</td>
</tr>
<tr>
<td>Change from baseline (mean)</td>
<td>0.5</td>
<td>-0.6</td>
<td>-0.8</td>
</tr>
<tr>
<td>Difference from metformin alone (adjusted mean)</td>
<td></td>
<td>-1.0\textsuperscript{t}</td>
<td>-1.2\textsuperscript{t}</td>
</tr>
<tr>
<td>% of patients with HbA1c ≥ 0.7% decrease from baseline</td>
<td>11%</td>
<td>45%</td>
<td>52%</td>
</tr>
</tbody>
</table>

1. P < 0.0001 compared with metformin.

In a second 26 week trial, patients with type 2 diabetes inadequately controlled on 2.5 grams/day of metformin who were randomized to receive the combination of rosiglitazone 4 mg twice daily and metformin (N = 105) showed a statistically significant improvement in glycemic control with a mean treatment effect for FPG of -56 mg/dL and a mean treatment
effect for HbA1c of -0.8% over metformin alone. The combination of metformin and rosiglitazone resulted in lower levels of FPG and HbA1c than either agent alone.

15 REFERENCES


16 HOW SUPPLIED/STORAGE AND HANDLING

Rosiglitazone maleate and metformin hydrochloride tablets are available as follows:

1 mg/500 mg – yellow, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7530” on the other side of the tablet, in bottles of 60 (NDC 0093-7530-06) and 100 (NDC 0093-7530-01).

2 mg/500 mg – light-pink, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7531” on the other side of the tablet, in bottles of 60 (NDC 0093-7531-06), 100 (NDC 0093-7531-01), and 500 (NDC 0093-7531-05).

4 mg/500 mg – orange, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7532” on the other side of the tablet, in bottles of 60 (NDC 0093-7532-06), 100 (NDC 0093-7532-01), and 500 (NDC 0093-7532-05).

2 mg/1,000 mg – yellow, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7533” on the other side of the tablet, in bottles of 60 (NDC 0093-7533-06) and 100 (NDC 0093-7533-01).

4 mg/1,000 mg – pink, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7534” on the other side of the tablet, in bottles of 60 (NDC 0093-7534-06) and 100 (NDC 0093-7534-01).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

There are multiple medications available to treat type 2 diabetes. The benefits and risks of each available diabetes medication should be taken into account when choosing a particular diabetes medication for a given patient.

Patients should be informed of the following:

- The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue rosiglitazone maleate and metformin hydrochloride tablets immediately and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of rosiglitazone maleate and metformin hydrochloride tablets, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.
- Avoid excessive alcohol intake, either acute or chronic, while receiving rosiglitazone maleate and metformin hydrochloride tablets.
- Rosiglitazone maleate and metformin hydrochloride tablets are not recommended for patients with symptomatic heart failure.
• A meta-analysis of mostly short-term trials suggested an increased risk for myocardial infarction with rosiglitazone compared with placebo. Data from long-term clinical trials of rosiglitazone versus other antidiabetes agents (metformin or sulfonylureas), including a cardiovascular outcome trial (RECORD), observed no difference in overall mortality or in major adverse cardiovascular events (MACE) and its components.
• Rosiglitazone maleate and metformin hydrochloride tablets are not recommended for patients who are taking insulin.
• Management of type 2 diabetes should include diet control. Caloric restriction, weight loss, and exercise are essential for the proper treatment of the diabetic patient because they help improve insulin sensitivity. This is important not only in the primary treatment of type 2 diabetes but also in maintaining the efficacy of drug therapy.
• It is important to adhere to dietary instructions and to regularly have blood glucose, glycosylated hemoglobin (HbA1c), renal function, and hematologic parameters tested. It can take 2 weeks to see a reduction in blood glucose and 2 to 3 months to see the full effect of rosiglitazone maleate and metformin hydrochloride tablets.
• Instruct patients to inform their doctor that they are taking rosiglitazone maleate and metformin hydrochloride tablets prior to any surgical or radiological procedure, as temporary discontinuation of rosiglitazone maleate and metformin hydrochloride tablets may be required until renal function has been confirmed to be normal [see Warnings and Precautions (5.1)].
• Blood will be drawn to check their liver function prior to the start of therapy and periodically thereafter per the clinical judgment of the healthcare professional. Patients with unexplained symptoms of nausea, vomiting, abdominal pain, fatigue, anorexia, or dark urine should immediately report these symptoms to their physician.
• Patients who experience an unusually rapid increase in weight or edema or who develop shortness of breath or other symptoms of heart failure while on rosiglitazone maleate and metformin hydrochloride tablets should immediately report these symptoms to their physician.
• Therapy with rosiglitazone maleate and metformin hydrochloride tablets, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking rosiglitazone maleate and metformin hydrochloride tablets. Thus, adequate contraception in premenopausal women should be recommended. This possible effect has not been specifically investigated in clinical trials so the frequency of this occurrence is not known.

All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA, Inc.

Manufactured In Israel By:

Teva Pharmaceutical Ind. Ltd.
Jerusalem, 9777402, Israel

Manufactured For:

Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454

Iss. 4/2017

MEDICATION GUIDE

ROSIGLITAZONE MALEATE (roh-zee-GLIT-ah-zohn MAL-ee-ate) AND METFORMIN HYDROCHLORIDE (met-FORE-min hye-droe-KLOR-ide) TABLETS

Read this Medication Guide carefully before you start taking rosiglitazone maleate and metformin hydrochloride tablets and each time you get a refill. There may be new information. This information does not take the place of talking with
your doctor about your medical condition or your treatment. If you have any questions about rosiglitazone maleate and metformin hydrochloride tablets, ask your doctor or pharmacist.

**What is the most important information I should know about rosiglitazone maleate and metformin hydrochloride tablets?**

**Rosiglitazone maleate and metformin hydrochloride tablets may cause serious side effects, including:**

**New or worse heart failure**

- The risk of heart failure may be higher in people who take rosiglitazone maleate and metformin hydrochloride tablets with insulin. Most people who take insulin should not also take rosiglitazone maleate and metformin hydrochloride tablets.
- Rosiglitazone, one of the medicines in rosiglitazone maleate and metformin hydrochloride tablets, can cause your body to keep extra fluid (fluid retention), which leads to swelling (edema) and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure. Heart failure means your heart does not pump blood well enough.
- If you have severe heart failure, you cannot start rosiglitazone maleate and metformin hydrochloride tablets.
- If you have heart failure with symptoms (such as shortness of breath or swelling), even if these symptoms are not severe, rosiglitazone maleate and metformin hydrochloride tablets may not be right for you.

Call your doctor right away if you have any of the following:

- swelling or fluid retention, especially in the ankles or legs
- shortness of breath or trouble breathing, especially when you lie down
- an unusually fast increase in weight
- unusual tiredness

**Lactic acidosis**

**Metformin, one of the medicines in rosiglitazone maleate and metformin hydrochloride tablets, can cause a rare but serious condition called lactic acidosis (a buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital.**

Call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis:

- you feel cold in your hands or feet
- you feel dizzy or lightheaded
- you have a slow or irregular heartbeat
- you feel very weak or tired
- you have unusual (not normal) muscle pain
- you have trouble breathing
- you feel sleepy or drowsy
- you have stomach pains, nausea, or vomiting

Most people who have had lactic acidosis with metformin have other things that, combined with the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with rosiglitazone maleate and metformin hydrochloride tablets if you:

- have severe kidney problems or your kidneys are affected by certain x-ray tests that use injectable dye.
- have liver problems
- drink alcohol very often, or drink a lot of alcohol in short-term “binge” drinking
• get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity or exercise and do not drink enough fluids.
• have surgery
• have a heart attack, severe infection, or stroke

The best way to keep from having a problem with lactic acidosis from metformin is to tell your doctor if you have any of the problems in the list above. Your doctor may decide to stop your rosiglitazone maleate and metformin hydrochloride tablets for a while if you have any of these things.

Rosiglitazone maleate and metformin hydrochloride tablets can have other serious side effects. See “What are the possible side effects of rosiglitazone maleate and metformin hydrochloride tablets?”

What are rosiglitazone maleate and metformin hydrochloride tablets?

Rosiglitazone maleate and metformin hydrochloride tablets contain two prescription medicines for treating diabetes, rosiglitazone maleate (AVANDIA®) and metformin hydrochloride. Rosiglitazone maleate and metformin hydrochloride tablets are used, with diet and exercise, to treat adults with type 2 (“adult-onset” or “non-insulin dependent”) diabetes (“high blood sugar”).

Metformin works mainly by decreasing the production of sugar by your liver. Rosiglitazone helps your body respond better to its natural insulin and does not cause your body to make more insulin. These medicines work together to help control your blood sugar. Rosiglitazone maleate and metformin hydrochloride tablets may be used alone or with other diabetes medicines.

Rosiglitazone maleate and metformin hydrochloride tablets are not for people with type 1 diabetes mellitus or to treat a condition called diabetic ketoacidosis.

It is not known if rosiglitazone maleate and metformin hydrochloride tablets are safe and effective in children younger than 18 years old.

Who should not take rosiglitazone maleate and metformin hydrochloride tablets?

Do not take rosiglitazone maleate and metformin hydrochloride tablets if you:

• have severe kidney problems. Before you take rosiglitazone maleate and metformin hydrochloride tablets and while you take them, your doctor should test your blood to check for signs of kidney problems.
• have a condition known as metabolic acidosis, including diabetic ketoacidosis.

Many people with heart failure should not start taking rosiglitazone maleate and metformin hydrochloride tablets. See “What should I tell my doctor before taking rosiglitazone maleate and metformin hydrochloride tablets?”

Do not take rosiglitazone maleate and metformin hydrochloride tablets if you are allergic to rosiglitazone or any of the inactive ingredients in rosiglitazone maleate and metformin hydrochloride tablets. See the end of this leaflet for a complete list of ingredients in rosiglitazone maleate and metformin hydrochloride tablets.

Symptoms of a severe allergic reaction with rosiglitazone maleate and metformin hydrochloride tablets may include:

• swelling of your face, lips, tongue, or throat
• problems with breathing or swallowing
• skin rash or itching
• raised red areas on your skin (hives)
• blisters on your skin or in your mouth, nose, or eyes
• peeling of your skin
• fainting or feeling dizzy
• very rapid heartbeat

What should I tell my doctor before taking rosiglitazone maleate and metformin hydrochloride tablets?

Before starting rosiglitazone maleate and metformin hydrochloride tablets, ask your doctor about what the choices are for diabetes medicines, and what the expected benefits and possible risks are for you in particular.

Before taking rosiglitazone maleate and metformin hydrochloride tablets, tell your doctor about all of your medical conditions, including if you:

• have heart problems or heart failure.
• have severe kidney problems.
• have type 1 (“juvenile”) diabetes or had diabetic ketoacidosis. These conditions should be treated with insulin.
• are going to have dye injected into a vein for an X-ray, CAT scan, heart study, or other type of scanning. Rosiglitazone maleate and metformin hydrochloride tablets may need to be stopped for a short time.
• drink a lot of alcohol (all the time or short binge drinking).
• develop a serious condition such as a heart attack, severe infection, or a stroke.
• have a type of diabetic eye disease called macular edema (swelling of the back of the eye).
• have liver problems. Your doctor should do blood tests to check your liver before you start taking rosiglitazone maleate and metformin hydrochloride tablets and during treatment as needed.
• had liver problems while taking REZULIN™ (troglitazone), another medicine for diabetes.
• are pregnant or plan to become pregnant. It is not known if rosiglitazone maleate and metformin hydrochloride tablets can harm your unborn baby. You and your doctor should talk about the best way to control your diabetes during pregnancy. If you are a premenopausal woman (before the “change of life”) who does not have regular monthly periods, rosiglitazone maleate and metformin hydrochloride tablets may increase your chances of becoming pregnant. Talk to your doctor about birth control choices while taking rosiglitazone maleate and metformin hydrochloride tablets. Tell your doctor right away if you become pregnant while taking rosiglitazone maleate and metformin hydrochloride tablets.
• are breastfeeding or planning to breastfeed. It is not known if rosiglitazone and metformin pass into breast milk. You and your doctor should decide if you will take rosiglitazone maleate and metformin hydrochloride tablets or breastfeed. You should not do both.

Tell your doctor about all of the medicines you take including prescription and over-the-counter medicines, vitamins, or herbal supplements. Rosiglitazone maleate and metformin hydrochloride tablets and certain other medicines can affect each other and may lead to serious side effects including high or low blood sugar, or heart problems. Your doctor may need to change your dose of rosiglitazone maleate and metformin hydrochloride tablets or your other medicines. Especially tell your doctor if you take:

• insulin.
• any medicines for high blood pressure, high cholesterol, or heart failure, or for prevention of heart disease or stroke.

Know the medicines you take. Keep a list of all your medicines and show it to your doctor and pharmacist before you start a new medicine. They will tell you if it is alright to take rosiglitazone maleate and metformin hydrochloride tablets with other medicines.

How should I take rosiglitazone maleate and metformin hydrochloride tablets?

• Take rosiglitazone maleate and metformin hydrochloride tablets exactly as prescribed. Your doctor may need to change your dose until your blood sugar is better controlled.
Rosiglitazone maleate and metformin hydrochloride tablets should be taken by mouth and with meals.

Rosiglitazone maleate and metformin hydrochloride tablets may be prescribed alone or with other diabetes medicines. This will depend on how well your blood sugar is controlled.

It can take 2 weeks for rosiglitazone maleate and metformin hydrochloride tablets to start lowering your blood sugar. It may take 2 to 3 months to see the full effect on your blood sugar level.

If you miss a dose of rosiglitazone maleate and metformin hydrochloride tablets, take it as soon as you remember, unless it is time to take your next dose. Take your next dose at the usual time. Do not take double doses to make up for a missed dose.

If you take too many rosiglitazone maleate and metformin hydrochloride tablets, call your doctor or poison control center right away.

Test your blood sugar regularly as your doctor tells you.

Diet and exercise can help your body use its blood sugar better. It is important to stay on your recommended diet, lose extra weight, and get regular exercise while taking rosiglitazone maleate and metformin hydrochloride tablets.

Your doctor should do blood tests to check your liver and kidneys before you start rosiglitazone maleate and metformin hydrochloride tablets and during treatment as needed. Your doctor should also do regular blood sugar tests (for example, “A1C”) to monitor your response to rosiglitazone maleate and metformin hydrochloride tablets.

There may be times when you will need to stop taking rosiglitazone maleate and metformin hydrochloride tablets for a short time. Tell your doctor if you:

- are sick with severe vomiting, diarrhea, or fever, or if you drink a much lower amount of liquid than normal.
- plan to have surgery.

**What should I avoid while taking rosiglitazone maleate and metformin hydrochloride tablets?**

Do not drink a lot of alcohol while taking rosiglitazone maleate and metformin hydrochloride tablets. This means you should not “binge drink”, and you should not drink a lot of alcohol on a regular basis. Drinking a lot of alcohol can increase the chance of getting lactic acidosis.

**What are possible side effects of rosiglitazone maleate and metformin hydrochloride tablets?**

**Rosiglitazone maleate and metformin hydrochloride tablets may cause serious side effects, including:**

- **New or worse heart failure.** See “What is the most important information I should know about rosiglitazone maleate and metformin hydrochloride tablets?”
- **Heart attack.** Rosiglitazone maleate and metformin hydrochloride tablets may increase the risk of a heart attack. Talk to your doctor about what this means to you.

**Symptoms of a heart attack can include the following:**

- chest discomfort in the center of your chest that lasts for more than a few minutes, or that goes away or comes back
- chest discomfort that feels like uncomfortable pressure, squeezing, fullness, or pain
- pain or discomfort in your arms, back, neck, jaw, or stomach
- shortness of breath with or without chest discomfort
- breaking out in a cold sweat
- nausea or vomiting
- feeling lightheaded

Call your doctor or go to the nearest hospital emergency room right away if you think you are having a heart attack.
• **Swelling (edema).** Rosiglitazone maleate and metformin hydrochloride tablets can cause swelling due to fluid retention. See “What is the most important information I should know about rosiglitazone maleate and metformin hydrochloride tablets?”

• **Weight gain.** Rosiglitazone, one of the medicines in rosiglitazone maleate and metformin hydrochloride tablets, can cause weight gain that may be due to fluid retention or extra body fat. Metformin, the other medicine in rosiglitazone maleate and metformin hydrochloride tablets, can cause weight loss. There is little change in weight with rosiglitazone maleate and metformin hydrochloride tablets. Weight gain can be a serious problem for people with certain conditions including heart problems. See “What is the most important information I should know about rosiglitazone maleate and metformin hydrochloride tablets?”

• **Liver problems.** It is important for your liver to be working normally when you take rosiglitazone maleate and metformin hydrochloride tablets. Your doctor should do blood tests to check your liver before you start taking rosiglitazone maleate and metformin hydrochloride tablets and during treatment as needed. Call your doctor right away if you have unexplained symptoms such as:
  o nausea or vomiting
  o stomach pain
  o unusual or unexplained tiredness
  o loss of appetite
  o dark urine
  o yellowing of your skin or the whites of your eyes.

• **Macular edema** (a diabetic eye disease with swelling in the back of the eye). Tell your doctor right away if you have any changes in your vision. Your doctor should check your eyes regularly. Very rarely, some people have had vision changes due to swelling in the back of the eye while taking rosiglitazone, one of the medicines in rosiglitazone maleate and metformin hydrochloride tablets.

• **Fractures (broken bones),** usually in the hand, upper arm, or foot. Talk to your doctor for advice on how to keep your bones healthy.

• **Low red blood cell count (anemia).**

• **Low blood sugar (hypoglycemia).** Lightheadedness, dizziness, shakiness, or hunger may mean that your blood sugar is too low. This can happen if you skip meals, if you use another medicine that lowers blood sugar, or if you have certain medical problems. Call your doctor if low blood sugar levels are a problem for you.

• **Ovulation** (release of egg from an ovary in a woman) leading to pregnancy. Ovulation may happen in premenopausal women who do not have regular monthly periods. This can increase the chance of pregnancy. See “What should I tell my doctor before taking rosiglitazone maleate and metformin hydrochloride tablets?”

**Common side effects of rosiglitazone maleate and metformin hydrochloride tablets include:**

• **Diarrhea, nausea, and upset stomach.** These side effects usually happen during the first few weeks of treatment. Taking rosiglitazone maleate and metformin hydrochloride tablets with food can help lessen these side effects. If you have unusual or unexpected stomach problems, talk with your doctor. Stomach problems that start up later during treatment with rosiglitazone maleate and metformin hydrochloride tablets may be a sign of something more serious and should be discussed with your doctor.

• **Cold-like symptoms**
• **Headache**
• **Joint aches**
• **Dizziness**

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store rosiglitazone maleate and metformin hydrochloride tablets?**

• Store rosiglitazone maleate and metformin hydrochloride tablets at room temperature, 59°F to 86°F (15°C to 30°C).
• Keep rosiglitazone maleate and metformin hydrochloride tablets in the container they come in. Keep the container closed tightly.
• Safely, throw away rosiglitazone maleate and metformin hydrochloride tablets that are out of date or no longer needed.

Keep rosiglitazone maleate and metformin hydrochloride tablets and all medicines out of the reach of children.

**General information about rosiglitazone maleate and metformin hydrochloride tablets**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use rosiglitazone maleate and metformin hydrochloride tablets for a condition for which they were not prescribed. Do not give rosiglitazone maleate and metformin hydrochloride tablets to other people, even if they have the same symptoms you have. They may harm them.

This Medication Guide summarizes important information about rosiglitazone maleate and metformin hydrochloride tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about rosiglitazone maleate and metformin hydrochloride tablets that is written for healthcare professionals. You can also find out more about rosiglitazone maleate and metformin hydrochloride tablets by calling 1-888-838-2872.

**What are the ingredients in rosiglitazone maleate and metformin hydrochloride tablets?**

Active Ingredients: rosiglitazone maleate and metformin hydrochloride

Inactive Ingredients: colloidal silicon dioxide, corn starch, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, and titanium dioxide. Additionally, 1 mg/500 mg tablets contain iron oxide yellow, 2 mg/500 mg tablets contain iron oxide red, 4 mg/500 mg tablets contain iron oxide red and iron oxide yellow, 2 mg/1,000 mg tablets contain iron oxide yellow, 4 mg/1,000 mg tablets contain iron oxide black and iron oxide red.

Always check to make sure that the medicine you are taking is the correct one. Rosiglitazone maleate and metformin hydrochloride tablets are oval and look like this:

- 1 mg/500 mg – yellow, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7530” on the other side of the tablet.
- 2 mg/500 mg – light-pink, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7531” on the other side of the tablet.
- 4 mg/500 mg – orange, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7532” on the other side of the tablet.
- 2 mg/1,000 mg – yellow, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7533” on the other side of the tablet.
- 4 mg/1,000 mg – pink, film-coated, modified oval-shaped tablets, debossed with “93” on one side and “7534” on the other side of the tablet.

**This Medication Guide has been approved by the U.S. Food and Drug Administration.**

All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA, Inc.

Manufactured In Israel By:

**Teva Pharmaceutical Ind. Ltd.**

Jerusalem, 9777402, Israel
Manufactured For:

Teva Pharmaceuticals USA, Inc.

North Wales, PA 19454

Iss. 4/2017